Amylyx Pharmaceuticals, Inc. 10-Q filing
Filed 2025-08-07 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001193125-25-174948
- Form type
- 10-Q
- CIK
- 0001658551
- Primary document
- https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amylyx Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $0 | - | - |
| Cost Of Revenue | $0 | - | - |
| Operating Income | $-80.7M | - | - |
| Net Income | $-77.3M | - | - |
| Eps Basic | -0.88 | - | - |
| Eps Diluted | -0.88 | - | - |
| Cash And Equivalents | $58.1M | - | - |
| Total Assets | $194.6M | - | - |
| Total Liabilities | $26.7M | - | - |
| Shareholders Equity | $167.9M | - | - |
| Operating Cash Flow | $-65.1M | - | - |
| Capital Expenditures | $28,000 | - | - |